Welcome, Guest. Please login or register.
June 15, 2024, 03:23:06 pm

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55127
  • Total Topics: 4851
  • Online Today: 117
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 83
Total: 83


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Janssen New Quadruple Combo Cures 100% of Hep C Genotype 1b  (Read 6571 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Janssen New Quadruple Combo Cures 100% of Hep C Genotype 1b
« on: March 31, 2015, 01:01:11 pm »
The HPC2001 study was a Phase IIa trial of 12 weeks of Olysio plus one or two of Jannsen's upcoming additional direct-acting antivirals.

Treatment was given to both treatment-naive and prior relapser individuals with genotype 1 of the virus who did not have cirrhosis.

In three groups, Olysio was paired with the non-nucleoside polymerase inhibitor TMC647055, which was boosted with the HIV antiretroviral Norvir (ritonavir), with or without ribavirin.

A fourth group took Olysio, Norvir–boosted TMC647055, and either 30 or 60 milligrams of the NS5A replication complex inhibitor JNJ-56914845.

Check out details on the results here: http://www.hepmag.com/articles/Olysio_1b_2501_26982.shtml


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.